Laddar...
Assessment and Management of Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T Cell Therapy
INTRODUCTION: The success of CD19 chimeric antigen receptor (CAR)-T cell therapy for treatment of CD19 positive malignancies has led to the FDA approval of two CD19 CAR-T cell products, tisagenlecleucel and axicabtagene ciloleucel, and ongoing clinical trials of new products. Cytokine release syndro...
Sparad:
| I publikationen: | Expert Opin Biol Ther |
|---|---|
| Huvudupphovsmän: | , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2020
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7393694/ https://ncbi.nlm.nih.gov/pubmed/32067497 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14712598.2020.1729735 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|